@truthtracer Investors should start valuing how much revenues eventual success a $JNJ + $ARWR CHBV-drug will bring. Reasonable assumption there will be success. Equally reasonable assumption competitors to take awhile to match $JNJ + $ARWR HBV drug regimen, if at all.  $DRNA $ALNY $ABUS $VIR